Noncardiac applications of glycoprotein IIb/IIIa inhibitors

Catheterization and Cardiovascular Interventions

Volumn 62, Issue 4, 2004, Pages 530-538

  Almeda, Francis Q ^a,b   Schaer, Gary L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Ingalls Memorial Hospital   (United States)

Author keywords

Angioplasty; Atherosclerosis; Glycoprotein IIb IIIa inhibitor; Glycoprotein IIb IIIa receptor; Peripheral arterial occlusive disease; Peripheral vascular disease; Platelet; Platelet glycoprotein; Platelet inhibitor; Stent; Stroke

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; TIROFIBAN; UROKINASE;

ANTICOAGULATION; ATHEROSCLEROSIS; BLEEDING; BLOOD FILTER; BRAIN HEMORRHAGE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY STENT; DEVICE; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; EMBOLISM PROTECTION DEVICE; HEART INFARCTION; HUMAN; IMMUNOGENICITY; LIMB ISCHEMIA; NON ST SEGMENT ELEVATION HEART INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION HEART INFARCTION; STENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VERTEBRAL ARTERY STENOSIS;

ACUTE DISEASE; ANGIOPLASTY, BALLOON; BLOOD PLATELETS; BRAIN ISCHEMIA; COMBINED MODALITY THERAPY; EXTREMITIES; HUMANS; INTEGRIN BETA3; ISCHEMIA; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEIN IIB; PRACTICE GUIDELINES AS TOPIC; STROKE; THROMBOEMBOLISM; VASCULAR DISEASES;

EID: 3843088689     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20133     Document Type: Review

References (59)

1. Limbruno U, Micheli A, De Carlo M, Amoroso G, Rossini R, Palagi C, Di Bello V, Petronio AS, Fontanini G, Mariani M. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003;108:171-176.
2. Henriques JP, Zijlstra F, Ottervanger JP, de Boer MJ, van't Hof AW, Hoorntje JC, Suryapranata H. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002;23:1112-1117.
3. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001;22:729-739.
4. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332: 1553-1559.
5. Almeda FQ, Snell RJ, Parrillo JE. The contemporary management of acute myocardial infarction. Crit Care Clin 2001;17:411-434.
6. ASSENT-3. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
7. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
8. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
9. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-1887.
10. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
11. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
12. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, et al. Multicenter. randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention: IMPACT investigators. Circulation 1995;91:2151-2157.
13. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial-a randomized controlled trial. JAMA 2001; 285:2468-2473.
14. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Sapp S, Califf RM. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6.
15. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
16. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
17. Vorchheimer DA, Badimon JJ, Fuster V. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999;281:1407-1414.
18. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000;101: 570-580.
19. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-1671.
20. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-542.
21. CAPTURE study. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997;349:1429-1435.
22. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
23. EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
24. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
25. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
26. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II): Second European-Australasian Acute Stroke Study investigators. Lancet 1998;352:1245-1251.
27. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-1150.
28. Duke RJ, Bloch RF, Turpie AG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986;105:825-828.
29. International Stroke Trial collaborative group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.
30. Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998;279: 1265-1272.
31. Chinese Acute Stroke Trial collaborative group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
32. Cohen SA, Trikha M, Mascelli MA. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol Oncol Res 2000; 6:163-174.
33. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
34. Kaku S, Umemura K, Mizuno A, Yano S, Suzuki K, Kawasaki T, Nakashima M. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol 1998;345:185-192.
35. Abciximab in Ischemic Stroke investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000;31:601-609.
36. AbESTT. Preliminary results of the Abciximab in Emergent Stroke Treatment Trial (AbESTT). Phoenix, AZ: American Stroke Association's 28th International Stroke Conference. 2003.
37. Spencer MP, Thomas GI, Nicholls SC, Sauvage LR. Detection of middle cerebral artery emboli during carotid endarterectomy using transcranial Doppler ultrasonography. Stroke 1990;21:415-423.
38. Spencer MP. Transcranial Doppler monitoring and causes of stroke from carotid endarterectomy. Stroke 1997;28:685-691.
39. Jordan WD Jr, Voellinger DC, Doblar DD, Plyushcheva NP, Fisher WS, McDowell HA. Microemboli detected by transcranial Doppler monitoring in patients during carotid angioplasty versus carotid endarterectomy. Cardiovasc Surg 1999;7:33-38.
40. Qureshi AI, Suri MF, Khan J, Fessler RD, Guterman LR, Hopkins LN. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience. Neurosurgery 2000;46: 1316-1324.
41. Kapadia SR, Bajzer CT, Ziada KM, Bhatt DL, Wazni OM, Silver MJ, Beven EG, Ouriel K, Yadav JS. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke 2001;32: 2328-2332.
42. Hofmann R, Kerschner K, Steinwender C, Kypta A, Bibl D, Leisch F. Abciximab bolus injection does not reduce cerebral ischemic complications of elective carotid artery stenting: a randomized study. Stroke 2002;33:725-727.
43. Schneiderman J, Morag B, Gerniak A, Rimon U, Varon D, Seligsohn U, Shotan A, Adar R. Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results. J Endovasc Ther 2000;7:263-272.
44. Qureshi AI, Ali Z, Suri MF, Kim SH, Fessler RD, Ringer AJ, Guterman LR, Hopkins LN. Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement. Neurosurgery 2001;48:998-1004.
45. Wholey HM, Eles G, Toursakissian B, Bailey S, Jarmolowski C, Tan WA. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. J Endovasc Ther 2003;10:33-41.
46. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR III, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884-892.
47. Dawson DL, Hiatt WR, Creager MA, Hirsch AT. Peripheral arterial disease: medical care and prevention of complications. Prev Cardiol 2002;5:119-130.
48. Tepe G, Schott U, Erley CM, Albes J, Claussen CD, Duda SH. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis. Am J Roentgenol 1999;172:1343-136.
49. Benenati J, Shlansky-Goldberg R, Meglin A, Seidl E. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. J Vasc Interv Radiol 2001;12: 795-805.
50. Schweizer J, Kirch W, Koch R, Muller A, Hellner G, Forkmann L. Short- and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 2000;51:913-923.
51. Duda SH, Tepe G, Luz O, Ouriel K, Dietz K, Hahn U, Pereira P, Marsalek P, Ziemer G, Erley CM, Claussen CD. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone-a randomized pilot trial (the PROMPT study). Radiology 2001;221:689-696.
52. Haas PC, Yaryura R, Krajeer Z, Strickman NE. Use of a glycoprotein IIa/IIIa receptor antagonist (abciximab) in peripheral vascular interventions. Am J Cardiol 1997;80:46S.
53. Ambrosini V, Battaglia S, Cioppa A, Lo Muzio L, Salemme L, Sorropago G, Tesoria T, Rubino P. Percutaneous femoral artery angioplasty with stent-in-stent technique and tirofiban administration. J Invas Cardiol 2002;14:619-623.
54. Berkompas DC. Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis. Cathet Cardiovasc Diagn 1998;45:272-274.
55. SAPPHIRE trial. Preliminary results of the SAPPHIRE trial. Chicago: Annual Scientific Sessions of the American Heart Association; 2002.
56. Mintz EP, Gruberg L, Kouperberg E, Beyar R. Vertebral artery stenting using distal emboli protection and transcranial Doppler. Catheter Cardiovasc Interv 2004;61:12-15.
57. SECURITY trial. Preliminary results of the SECURITY trial. Washington, DC: Transcatheter Therapeutics. 2003.
58. ARCHER trial. Preliminary results of the ARCHER trial. Chicago: Annual Scientific Sessions of the American College of Cardiology. 2004.
59. SAPPHIRE trial. Preliminary results of the SAPPHIRE trial. Washington, DC: Transcatheter Therapeutics. 2002.